Bristol Myers Squibb, SystImmune gets USFDA Breakthrough Therapy Designation for izalontamab brengitecan for previously treated Advanced EGFR Mutated Non Small Cell Lung Cancer Ruchika Sharma19 Aug 2025 2:15 PM ISTPrinceton: SystImmune Inc., a clinical-stage biotechnology company, and Bristol Myers Squibb have announced that the U.S. Food and Drug...
Bristol Myers Squibb Breyanzi application accepted for priority review by USFDA for Marginal Zone Lymphoma Ruchika Sharma5 Aug 2025 12:20 PM ISTPrinceton: Bristol Myers Squibb has announced that the U.S. Food and Drug Administration (FDA) has accepted the supplemental biologics license...
Bristol Myers Squibb, Bain Capital form new biopharmaceutical company - NewCo Ruchika Sharma29 July 2025 12:30 PM ISTPrinceton: Bristol Myers Squibb and Bain Capital have announced the formation of a new independent biopharmaceutical company, NewCo, focused on...
CDSCO Panel Approves Phase IV Protocol Amendment for Bristol-Myers Squibb's Mavacamten Study Parthika Patel24 July 2025 6:49 PM ISTNew Delhi: The Subject Expert Committee (SEC) under the Cardiovascular division of the Central Drugs Standard Control Organisation (CDSCO) has...
Delhi HC Bars Zydus From Launching Cancer Drug Nivolumab Biosimilar Till 2026 Farhat Nasim23 July 2025 4:45 PM ISTNew Delhi: In a major setback to Zydus Lifesciences, the Delhi High Court has restrained the company from launching its proposed biosimilar of the...
Pfizer: Reshma Parida to become new Senior Director - People Experience Ruchika Sharma3 July 2025 3:57 PM ISTMumbai: Pfizer has announced the appointment of Reshma Parida as the new Senior Director - People Experience, effective August 1, 2025. ...
US FDA eliminates risk evaluation, mitigation strategies for CAR-T cancer therapies Jyoti Kumari30 Jun 2025 2:54 PM ISTBengaluru: The U.S. Food and Drug Administration said on Friday had eliminated risk evaluation and mitigation strategies (REMS), a safety program to...
USFDA approves label updates for Bristol Myers Squibb 2 CAR T cell therapies Ruchika Sharma29 Jun 2025 12:30 PM ISTPrinceton: Bristol Myers Squibb has announced that the U.S. Food and Drug Administration (FDA) has approved label updates for both of its CAR T...
Bristol Myers Squibb, BioNTech ink pact to co-develop, co-commercialize investigational bispecific antibody for multiple solid tumor types Ruchika Sharma6 Jun 2025 11:30 AM ISTPrinceton: BioNTech SE and Bristol Myers Squibb have announced that the companies have entered into an agreement for the global...
Bristol Myers Squibb bags European Commission nod for Subcutaneous formulation of Opdivo across multiple solid tumor indications Ruchika Sharma29 May 2025 10:00 AM ISTPrinceton: Bristol Myers Squibb has received approval from the European Commission (EC) for a new Opdivo (nivolumab) formulation...
Bristol Myers Squibb bags European Commission approval for Opdivo combo in lung cancer treatment Ruchika Sharma18 May 2025 11:45 AM ISTPrinceton: Bristol Myers Squibb has announced that the European Commission (EC) has approved the perioperative regimen of neoadjuvant...
Bristol Myers Squibb names Cari Gallman as Executive Vice President, General Counsel and Chief Policy Officer Ruchika Sharma7 May 2025 11:15 AM ISTPrinceton: Bristol Myers Squibb has announced the appointment of Cari Gallman as Executive Vice President, General Counsel and Chief Policy...
